ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

Wenlong Li(Tianjin University of Traditional Chinese Medicine), Alfred H. Schinkel(Oncode Institute), Rolf W. Sparidans(Slotervaartziekenhuis), Maria C. Lebre(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Margarida L.F. Martins(The Netherlands Cancer Institute), Mujtaba El-Lari(Oncode Institute), Olaf van Tellingen(Dutch Cancer Society)
Molecular Cancer Therapeutics
March 30, 2021
10.1158/1535-7163.mct-20-0705
Cited by 9

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688